8 147 Impact of Socioeconomic Status in Patients with Achilles Tendinopathy Table 3. Differences in VISA-A score between Q1 and Q5 at each time point (adjusted for sex, BMI, age, symptom duration and AAS). Values are displayed as mean (SD) P-values were Bonferroni corrected Group Difference 95% CI for difference Q1 Q5 Mean difference (± SE) P value Lower Bound Upper Bound Baseline (n = 45/39) 43.9 (20.9) 41.8 (17.9) 2.1 ± 3.9 0.59 -5.6 -3.7 -14.0 1.0 9.8 14.8 6.3 21.3 6 weeks* (n=35/29) 49.2 (18.8) 43.7 (18.7) 5.5 ± 4.6 0.24 12 weeks* (n=32/28) 50.7 (19.5) 54.5 (20.1) -3.8 ± 5.1 0.45 24 weeks* (n=29/26) 66.4 (18.9) 55.2 (18.9) 11.2† ± 5.0 0.03 *= also adjusted for baseline VISA-A score. † This difference exceeds the Minimal Clinically Important Difference (MCID) of 7-points at 24-weeks.40 Abbreviations: BMI: Body Mass Index (kg/m2), VISA-A: Victorian Institute of Sports Assessment-Achilles, AAS: Ankle Activity Score. CI: Confidence Interval Figure 1. The difference in VISA-A between Q1 and Q5 at each time point (adjusted for sex, Body Mass Index, age, symptom duration, Ankle Activity Score and baseline VISA-A score). Values are displayed as mean ± 95% confidence interval. * Indicates statistically significant difference (p = 0.03) exceeding the Minimal Clinically Important Difference (MCID). We applied the Bonferroni adjustment to adjust for multiple comparisons.
RkJQdWJsaXNoZXIy MTk4NDMw